Regimen Reference Order – BRST - ribociclib + letrozole +/- goserelin

To order this therapy in ARIA, refer to Additional Information below

Planned Course: **Until disease progression or unacceptable toxicity (1 cycle of ribociclib = 28 days)**

Indication for Use: **Breast Cancer Metastatic, Hormone Receptor Positive, HER2 negative**

CVAD: Not Required

Proceed with treatment if:

ribociclib

- ***ANC equal to or greater than 1 x 10^9/L AND Platelets equal to or greater than 75 x 10^9/L***

Aromatase Inhibitor and LHRH agonist

- ***Continued throughout therapy regardless of CBC. If ribociclib is held for toxicity, Aromatase Inhibitor and LHRH agonist are continued***
  - ❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – BRST – ribociclib + letrozole +/- goserelin

Drug	Dose	CCMB Administration Guideline
ribociclib	600 mg	Orally once daily on **Days 1 to 21, then 7 days off** Take with or without food Swallow whole **(Self-administered at home)**
letrozole **OR** alternate Aromatase Inhibitor (see options on table on Page 3)	2.5 mg	Orally once daily throughout therapy Take with or without food **(Self-administered at home)**
goserelin* **OR** alternate LHRH agonist* (see options on table on Page 3)	3.6 mg	Subcutaneous once every 28 days **(goserelin or alternate LHRH agonist starts 28 days prior to the start of aromatase inhibitor then continues throughout therapy)**
* LHRH agonists are only prescribed for pre- or peri-menopausal patients		
ribociclib (KISQALI®) available dosage strength: 200 mg tablet **Classification: Cytotoxic, Hazardous**		

In the event of an infusion-related hypersensitivity reaction, refer to the '**Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

EKG monitoring (for ribociclib)

- Prior to initiation of treatment, then
- Cycle 1, Day 14, then
- Cycle 2, Day 1, then
- at regular intervals thereafter during steady-state treatment (at approximately Day 14 of the cycle) and whenever clinically indicated

Cycles 1 and 2 (for ribociclib)

- CBC and biochemistry (including liver enzymes and total bilirubin) prior to Days 1 and 15 as per Physician Orders

Cycles 3 to 6 (for ribociclib)

- CBC and biochemistry (including liver enzymes and total bilirubin) prior to Day 1 and as clinically indicated as per Physician Orders
- No blood work required on Day 15

Cycle 7 and Onwards (for ribociclib)

- CBC prior to Day 1 at physician's discretion
  - Each cycle (if ANC was less than 1 x 10^9/L during first 6 cycles) or
  - Every 3rd cycle (if ANC was 1 x 10^9/L or greater during first 6 cycles)
- Biochemistry (including liver enzymes and total bilirubin) periodically as clinically indicated as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

DISCHARGE INSTRUCTIONS

- ribociclib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- ribociclib has potential for myelosuppression
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade), and starfruit with ribociclib
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on ribociclib

ADDITIONAL INFORMATION

- QT prolongation has been associated with ribociclib; dose interruptions and/or reductions may be required for QT prolongation
- Breast DSG oncologists may prescribe ribociclib in combination with different aromatase inhibitors and LHRH agonists
- Pre- and peri-menopausal patients initiate LHRH agonist therapy at least 4 weeks before starting treatment with ribociclib and aromatase inhibitor
- Due to the various combinations used with ribociclib, this Regimen Reference Order provides only one example of possible combinations. The tables on page 3 outline different drugs/dosing schedules which may be prescribed
- ribociclib dose interruptions and/or reductions may be required for neutropenia; If ribociclib is held for toxicity reasons, aromatase inhibitor and LHRH agonist therapy continue while ribociclib is held

- **ARIA ordering**: Please note that ARIA regimens/protocols require each drug to be ordered separately
  - **BRST – [ribociclib]** regimen is available as a 28-day cycle under the "Breast" treatment tab in ARIA
  - Support protocols are available for **anastrozole, exemestane,** and **letrozole** (90-day supply) under **Hormonal Therapy** in the "Breast Cancer" folder
  - Support protocols are available for **goserelin** and **leuprolide** (either q 28 days OR q 12 weeks) under **LHRH Agonists** in the "Breast Cancer" folder
- ribociclib will be dispensed by CCMB Pharmacy

Options for Aromatase Inhibitors

Drug	Dose	CCMB Administration Guideline
anastrozole	1 mg	Orally once daily throughout therapy Take with or without food **(Self-administered at home)**
OR		
exemestane	25 mg	Orally once daily throughout therapy Take after a meal **(Self-administered at home)**
OR		
letrozole	2.5 mg	Orally once daily throughout therapy Take with or without food **(Self-administered at home)**

anastrozole (ARIMIDEX®) available dosage strength: 1 mg tablet
Classification: Non-Cytotoxic, Hazardous

exemestane (AROMASIN®) available dosage strength: 25 mg tablet
Classification: Non-Cytotoxic, Hazardous

letrozole (FEMARA®) available dosage strength: 2.5 mg tablet
Classification: Non-Cytotoxic, Hazardous

Options for LHRH Agonists

Drug	Dose	CCMB Administration Guideline
goserelin	3.6 mg	Subcutaneous once every 28 days (4 weeks)
	OR	
	10.8 mg	Subcutaneous once every 84 days (12 weeks)
OR		
leuprolide	7.5 mg	Subcutaneous once every 28 days (4 weeks)
	OR	
	22.5 mg	Subcutaneous once every 84 days (12 weeks)

goserelin (ZOLADEX®) available dosage strengths: 3.6 mg, 10.8 mg syringe
Classification: Non-Cytotoxic, Hazardous

leuprolide (ELIGARD®) available dosage strengths: 7.5 mg, 22.5 mg syringe
Classification: Non-Cytotoxic, Hazardous